29.02.2012 • News

Brachem Raises $769 Million from Sale of Brenntag Shares

Luxembourg-based investment firm Brachem Acquisition said it has raised €577.5 million from the sale of shares in German chemicals distributor Brenntag.

While Europe's market for new listings remains quiet, several days of rallying markets this month have given bankers a chance to run accelerated deals for clients, either raising new money or allowing major shareholders to cut their stakes.

The size of the offering was increased to 7 million shares, from 5 million due to investor interest -- making it equivalent to 13.6% of the company's share capital.

Brachem, which holds shares in Brenntag for private equity groups BC Partners and Bain Capital as well as Goldman Sachs, said the shares were placed at €82.50.

Brachem said it had cut its stake in Brenntag to 13.7% through the sale.

BC Partners, the largest shareholder of the three, last sold down its stake in Brenntag in January when it agreed to a 90-day lock-up on the further sale of any shares. However, a source close to the deal said this had been waived due to high demand for the stock.

The offering was several times oversubscribed, a banker said.

 

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read